Abstract
Background Metabolic syndrome is a group of heritable metabolic traits that are highly associated with type 2 diabetes (T2DM). Classical interventions to T2DM include individual self-management of environmental risk factors such as improving diet quality, increasing physical activity and reducing smoking and alcohol consumptions, which decreases the risk of developing metabolic syndrome. However, it is poorly understood how the phenotypes of diabetes-related metabolic traits change with respect to lifestyle modifications at the individual level.
Methods In this study, we applied a whole-genome genotype-by-environment (GxE) interaction approach to describe how intermediate traits reflecting metabolic risk are affected by genetic variations and how this genetic risk can interact with lifestyle, which can vary, conditional on individual genetic differences. In the analysis, we used 12 diabetes-related metabolic traits and eight lifestyle covariates from the UK Biobank comprising 288,837 white British participants genotyped for 1,133,273 genome-wide single nucleotide polymorphisms.
Findings We found 17 GxE interactions, of which four modulated BMI and the others distributed across other traits. Modulation of genetic effects by physical activity was seen for four traits (glucose, HbA1c, C-reactive protein, systolic blood pressure), and by alcohol and smoking for three (BMI, glucose, waist-hip ratio; and BMI, diastolic and systolic blood pressure, respectively). We also found a number of significant phenotypic modulations by the lifestyle covariates, which were not attributed to the genetic effects in the model. Overall, modulation in the metabolic risk in response to the level of lifestyle covariates was clearly observed, and its direction and magnitude were varied depending on individual differences. We also showed that the metabolic risk inferred by our model was notably higher in T2DM prospective cases than controls.
Interpretation Our findings highlight the importance of individual genetic differences in the prevention and management of diabetes and suggest that the one-size-fits-all approach may not benefit all.
Funding This study has been supported by the Australian Research Council (DP 190100766, FT 160100229).
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study has been supported by the Australian Research Council (DP 190100766, FT 160100229). The UK Biobank is funded by the UK Department of Health, the Medical Research Council, the Scottish Executive, and the Wellcome Trust Medical Research Charity.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The current study was approved by the University of South Australia Human Research Ethics Committee. The UKBB was approved by the North West Multi-centre Research Ethics Committee (11/NW/0382).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The author list has been corrected.
Data Availability
The analyses conducted in this study were based on data accessed through the UK Biobank HTTP://www.ukbiobank.ac.uk
